Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 1/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 7/20 | 0.41 |
| ▸ | CES1 | P23141 | 5/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27319691 | 1.00 | LPAR1 (0.54) | LPAR1LPAR3CES2TSHRTHRB | |
| SCHEMBL12290440 | 1.00 | LPAR1 (0.54) | LPAR1LPAR3CES2TSHRTHRB | |
| SCHEMBL30278656 | 1.00 | LPAR1 (0.54) | LPAR1LPAR3CES2TSHRTHRB | |
| SCHEMBL1936480 | 1.00 | LPAR1 (0.54) | LPAR1LPAR3CES2TSHRTHRB | |
| SCHEMBL24761094 | 1.00 | LPAR1 (0.54) | LPAR1LPAR3CES2TSHRTHRB | |
| SCHEMBL23381380 | 1.00 | LPAR1 (0.54) | LPAR1LPAR3CES2TSHRTHRB | |
| SCHEMBL24761193 | 1.00 | LPAR1 (0.54) | LPAR1LPAR3CES2TSHRTHRB | |
| SCHEMBL23034428 | 1.00 | LPAR1 (0.54) | LPAR1LPAR3CES2TSHRTHRB | |
| SCHEMBL15424555 | 0.97 | — | — | |
| SCHEMBL804671 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024096577-A1 | COMPOUND COMPRISING FC-BINDING UNIT, AND CONJUGATE PREPARED USING SAME | 앱티스 주식회사 | 2024-05-10 | — | — | WO | disclosed |
| EP-2988732-B1 | MODIFIED HYDROGELS | ASCENDIS PHARMA AS (DK) | 2023-05-03 | — | — | EP | disclosed |
| CN-115458808-A | Method for producing lithium fluorosulfonate, nonaqueous electrolytic solution, and nonaqueous electrolyte secondary battery | 三菱化学株式会社 | 2022-12-09 | — | — | CN | disclosed |
| US-20220202837-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | disclosed |
| CN-113387375-A | Method for producing lithium fluorosulfonate, nonaqueous electrolyte solution, and nonaqueous electrolyte secondary battery | 三菱化学株式会社 | 2021-09-14 | — | — | CN | disclosed |
| CN-108502904-B | Method for producing lithium fluorosulfonate, nonaqueous electrolyte solution, and nonaqueous electrolyte secondary battery | 三菱化学株式会社 | 2021-06-08 | — | — | CN | disclosed |
| US-20200384137-A1 | 18F LABELING OF PROTEINS USING SORTASES | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2020-12-10 | — | — | US | disclosed |
| CN-111646489-A | Method for producing lithium fluorosulfonate, nonaqueous electrolyte solution, and nonaqueous electrolyte secondary battery | 三菱化学株式会社 | 2020-09-11 | — | — | CN | disclosed |
| CN-106882820-B | Method for producing lithium fluorosulfonate, nonaqueous electrolyte solution, and nonaqueous electrolyte secondary battery | 三菱化学株式会社 | 2020-05-29 | — | — | CN | disclosed |
| US-20200046742-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | disclosed |
| EP-2881394-B1 | CONDENSED RING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-9789180-B2 | D-amino acid derivative-modified peptidoglycan and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-17 | — | — | US | disclosed |
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-20170021013-A1 | D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-01-26 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| CN-104167564-A | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery | MITSUBISHI CHEM CORP | 2014-11-26 | — | — | CN | disclosed |
| CN-102754268-B | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery | MITSUBISHI CHEM CORP | 2014-11-19 | — | — | CN | disclosed |
| CN-103492319-A | Method for producing lithium fluorosulfonate, nonaqueous electrolyte solution, and nonaqueous electrolyte secondary battery | MITSUBISHI CHEM CORP | 2014-01-01 | — | — | CN | disclosed |
| US-20130203758-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-08 | — | — | US | disclosed |
| US-4147884-A | Liquid phase oxidation of unsaturated aldehydes to corresponding acids | ATLANTIC RICHFIELD COMPANY (US) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170021013-A1 | D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND METHODS OF USE THEREOF | DAO, DDOST, DNPEP | LPAR1 1542/4885LPAR3 2156/4885CES2 4340/4885 |
| US-20220202837-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | PTMS, QPCT, ANPEP | LPAR1 890/4885LPAR3 250/4885CES2 1667/4885 |
| US-20130203758-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, SLC10A1, HCCS | LPAR1 2006/4885LPAR3 2062/4885CES2 86/4885 |
| US-20200046742-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | PTMS, QPCT, ANPEP | LPAR1 890/4885LPAR3 250/4885CES2 1667/4885 |
| US-20200384137-A1 | 18F LABELING OF PROTEINS USING SORTASES | SORT1, ANPEP, SPG11 | LPAR1 3208/4885LPAR3 2100/4885CES2 1513/4885 |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | VIP, AQP1, PEF1 | LPAR1 3457/4885LPAR3 2783/4885CES2 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.